The Testosterone Debate in the U.S. Military: Pete Hegseth’s Take

When former Army Ranger and Fox News commentator Pete Hegseth took to the editorial page last week, he didn’t just fire off a quick tweet about the Department of Defense’s new hormone‑therapy guidelines. He wrote a full‑blown op‑ed that reads more like a conversation you’d have over coffee with a friend who’s a little worried about the future of the military.

Hegseth starts by recalling his own time in uniform, the clang of boots on concrete, the smell of diesel fuel, and the “brother‑in‑arms” feeling that made every mission feel personal. He says, in his own voice, that those memories are exactly why he’s uneasy about a policy that allows service members to take testosterone—or any hormone—without a clear, combat‑related justification.

According to Hegseth, the Department of Defense’s recent move to streamline medical gender‑affirmation care, which includes testosterone for transgender women, is well‑intentioned but perhaps short‑sighted. He argues that hormone therapy can have side‑effects—changes in mood, blood‑pressure fluctuations, even altered reaction times—that might, in theory, affect a soldier’s performance on the battlefield. He doesn’t claim that every individual will be impacted, just that the risk is “real enough” to warrant more discussion.

He then shifts gears, weaving in a few anecdotes about teammates who relied on each other’s physical reliability. “When you’re in a firefight, you can’t be wondering whether your teammate’s hormone dose is going to make them sluggish or hyper‑reactive,” he writes, pausing for a moment as if remembering a specific, though unverified, story. The point, he says, is that cohesion rests on predictability, and unpredictable medical regimens could, in his view, erode that trust.

Of course, Hegseth acknowledges the other side of the coin. He mentions that denying transgender service members access to appropriate medical care could hurt morale, lead to litigation, and send a damaging message about inclusion. He concedes that the military has historically adapted to new technologies and policies—think of the integration of women into combat roles—so maybe this is just another step forward.

What makes his piece feel more human than a dry policy analysis is the way he peppers it with personal asides: a quick “you know what I mean?” after a sentence, a half‑laughing acknowledgment that he’s not a medical expert, and a reluctant admission that he’s torn between protecting combat readiness and respecting individual rights.

In the final paragraph, Hegseth doesn’t hand out a neat solution. Instead, he calls for a “balanced, transparent review” that involves medical professionals, unit commanders, and perhaps even a modest pilot program. He urges the Pentagon to gather data—real‑world performance metrics—before drawing broad conclusions. In other words, he wants the conversation to stay open, data‑driven, and, hopefully, less partisan.

Whether you agree with Hegseth or not, his editorial is a reminder that military policy isn’t just about regulations on paper; it’s about the lived experience of the men and women wearing the uniform. The testosterone debate, like many others in the armed forces, sits at the intersection of science, ethics, and the gritty reality of combat. And that’s why the conversation deserves a few more thoughtful pauses.